Tissue inhibitor matrix metalloproteinase 1 (TIMP1) was a significant down-regulated protein in FSGS, while Annexin A13 (ANXA 13) resulted as the most promising up-regulated potential biomarker to distinguish peritoneal dialysis effluent exosomes of FSGS patients from no FSGS ones. This evidence concerns the gene TIMP1 and focal segmental glomerulosclerosis.